Kiniksa Pharmaceuticals International (KNSA) Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Receivables for 6 consecutive years, with $23.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables fell 26.39% year-over-year to $23.5 million; the trailing twelve-month figure through Jun 2026 stood at $23.5 million (down 26.39% YoY), and the FY2025 full-year result was $15.6 million, down 62.63% from the prior year.
• Receivables improved to $23.5 million in Q2 2026 per KNSA's latest filing, from $23.2 million in the prior quarter.
• Across five years, Receivables topped out at $51.7 million in Q3 2025 and bottomed at $3.0 million in Q3 2023.
• Historically, Receivables has averaged $23.0 million across 5 years, with a median of $22.2 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables plunged 74.78% in 2023, then surged 718.41% in 2024.
• Over 5 years, Receivables stood at $20.3 million in 2022, then grew by 4.68% to $21.3 million in 2023, then surged by 96.2% to $41.7 million in 2024, then tumbled by 62.63% to $15.6 million in 2025, then surged by 50.63% to $23.5 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $23.5 million, $23.2 million, and $15.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.